Literature DB >> 8276648

Total-body irradiation and cataract incidence: a randomized comparison of two instantaneous dose rates.

M Ozsahin1, Y Belkacemi, F Pene, C Dominique, L H Schwartz, C Uzal, D Lefkopoulos, B Gindrey-Vie, L Vitu-Loas, E Touboul.   

Abstract

PURPOSE: To assess the influence of instantaneous total-body irradiation dose rate in hematological malignancies, we randomized 157 patients according to different instantaneous dose rates. METHODS AND MATERIALS: Between December 10, 1986 and December 31, 1989 157 patients have undergone a total-body irradiation before bone-marrow transplantation according to two different techniques: either in one fraction (1000 cGy given to the midplane at the level of L4, and 800 cGy to the lungs) or in six fractions (1200 cGy over 3 consecutive days to the midplane at the level of L4, and 900 cGy to the lungs). Patients were randomized according to two instantaneous dose rates, called LOW and HIGH, in single-dose (6 vs. 15 cGy/min) and fractionated (3 vs. 6 cGy/min) TBI groups; there were 77 cases for the LOW and 80 for the HIGH groups, with 57 patients receiving single-dose (28 LOW, 29 HIGH) and 100 patients receiving fractionated total-body irradiation (49 LOW, 51 HIGH).
RESULTS: As of July 1992, 16 (10%) of 157 patients developed cataracts after 17 to 46 months, with an estimated incidence of 23% at 5 years. Four (5%) of 77 patients in the LOW group, 12 (15%) of 80 patients in the HIGH group developed cataracts, with 5-year estimated incidences of 12% and 34%, respectively (p = 0.03). Ten (18%) of 57 patients in the single-dose group, and 6 (6%) of 100 patients in the fractionated group developed cataracts, with 5-year estimated incidences of 39% and 13%, respectively (p = 0.02). When the subgroups were considered, in the single-dose group, 3 (11%) of 28 LOW patients, and 7 (24%) of 29 HIGH patients developed cataracts, with 5-year estimated incidences of 24% and 53%, respectively; in the fractionated group, 1 (2%) of 49 LOW patients, and 5 (10%) of 51 HIGH patients developed cataracts, with 5-year estimated incidences of 4% and 22%, respectively (single-dose LOW vs. single-dose HIGH vs. fractionated LOW vs. fractionated HIGH, p = 0.006). There was no statistically significant difference in terms of 5-year estimated cataract incidence between the patients receiving steroids and those not (30% vs. 25%, p = 0.22). Multivariate analyses revealed that the instantaneous dose rate was the only independent factor influencing the cataractogenesis (p = 0.04).
CONCLUSION: We conclude that the total-body irradiation regimen (instantaneous dose rate and/or fractionation) may have an influence on the development of cataracts following bone-marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8276648     DOI: 10.1016/0360-3016(94)90056-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

Review 1.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.

Authors:  Smita Bhatia
Journal:  Expert Rev Hematol       Date:  2011-08       Impact factor: 2.929

Review 2.  Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences.

Authors:  T D Miale; S Sirithorn; S Ahmed
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

3.  Retrospective, monocentric analysis of late effects after Total Body Irradiation (TBI) in adults.

Authors:  Tobias Bölling; David Christoph Kreuziger; Iris Ernst; Hassan Elsayed; Normann Willich
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

4.  Lauriston S. Taylor Lecture on radiation protection and measurements: what makes particle radiation so effective?

Authors:  Eleanor A Blakely
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

5.  Effect of electron contamination on in vivo dosimetry for lung block shielding during TBI.

Authors:  Ganesh Narayanasamy; Wilbert Cruz; Daniel L Saenz; Sotirios Stathakis; Niko Papanikolaou; Neil Kirby
Journal:  J Appl Clin Med Phys       Date:  2016-05-08       Impact factor: 2.102

6.  Integration of automation into an existing clinical workflow to improve efficiency and reduce errors in the manual treatment planning process for total body irradiation (TBI).

Authors:  David H Thomas; Brian Miller; Rachel Rabinovitch; Sarah Milgrom; Brian Kavanagh; Quentin Diot; Moyed Miften; Leah K Schubert
Journal:  J Appl Clin Med Phys       Date:  2020-05-19       Impact factor: 2.102

7.  Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.

Authors:  Y Belkacémi; F Pène; E Touboul; B Rio; V Leblond; N C Gorin; A Laugier; C Gemici; M Housset; M Ozsahin
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

Review 8.  Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions.

Authors:  Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht
Journal:  Front Pediatr       Date:  2021-12-03       Impact factor: 3.418

9.  Adverse Effects of Total Body Irradiation: A Two-Decade, Single Institution Analysis.

Authors:  Richard Pearlman; Renee Hanna; Jay Burmeister; Judith Abrams; Michael Dominello
Journal:  Adv Radiat Oncol       Date:  2021-05-19

10.  National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Naoya Ishibashi; Toshinori Soejima; Hiroki Kawaguchi; Takeshi Akiba; Masatoshi Hasegawa; Kouichi Isobe; Hitoshi Ito; Michiko Imai; Yasuo Ejima; Masaharu Hata; Keisuke Sasai; Emiko Shimoda; Toshiya Maebayashi; Masahiko Oguchi; Tetsuo Akimoto
Journal:  J Radiat Res       Date:  2018-07-01       Impact factor: 2.724

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.